Ameritas Investment Partners Inc. Has $636,000 Holdings in Haemonetics Corporation $HAE

Ameritas Investment Partners Inc. trimmed its position in shares of Haemonetics Corporation (NYSE:HAE) by 99.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,059 shares of the medical instruments supplier’s stock after selling 1,931,843 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in Haemonetics were worth $636,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC increased its holdings in Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of Haemonetics by 216.4% during the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 567 shares during the last quarter. Byrne Asset Management LLC acquired a new stake in shares of Haemonetics in the third quarter valued at $42,000. Hantz Financial Services Inc. raised its holdings in shares of Haemonetics by 792.1% in the third quarter. Hantz Financial Services Inc. now owns 1,124 shares of the medical instruments supplier’s stock valued at $55,000 after buying an additional 998 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new position in Haemonetics during the 2nd quarter worth about $64,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Performance

HAE opened at $63.28 on Friday. The business has a 50 day moving average of $70.13 and a 200-day moving average of $64.03. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. The stock has a market cap of $2.94 billion, a price-to-earnings ratio of 17.43, a PEG ratio of 1.30 and a beta of 0.28. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $87.32.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business had revenue of $338.97 million for the quarter, compared to analyst estimates of $331.90 million. During the same quarter in the prior year, the business earned $1.19 EPS. Haemonetics’s quarterly revenue was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, equities research analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Wall Street Analyst Weigh In

HAE has been the subject of several research analyst reports. CJS Securities upgraded shares of Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. Mizuho dropped their target price on Haemonetics from $90.00 to $80.00 and set an “outperform” rating for the company in a research report on Friday, February 6th. Robert W. Baird set a $81.00 price target on Haemonetics in a research note on Friday, February 6th. Citigroup lowered their price objective on Haemonetics from $88.00 to $75.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Haemonetics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $84.44.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.